66772 Federal Register / Vol. 75, No. 209 / Friday, October 29, 2010 / Notices 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Centers for Advanced Diagnostics and 

Experimental Therapeutics in Lung Diseases 

(CADET I). 

Date: November 18–19, 2010. 

Time: 6 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Keary A Cope, PhD, 

Scientific Review Officer, Office of Scientific 

Review, National Heart, Lung, and Blood 

Institute, 6701 Rockledge Drive, Room 7190, 

Bethesda, MD 20892–7924, (301) 435–2222, 

copeka@mail.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Common Pathogenetic Mechanisms of Lung 

Cancer and COPD. 

Date: November 19, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Robert T. Su, PhD, 

Scientific Review Officer, Review Branch/ 

DERA, National Heart, Lung, and Blood 

Institute, 6701 Rockledge Drive, Room 7202, 

Bethesda, MD 20892–7924, 301–435–0297, 

sur@mail.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Next Generation Genetic Association Studies. 

Date: November 19, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications, 

Place: Westin BWI (Baltimore), 1100 Old 

Elkridge Landing Road, Baltimore, MD 

21090. 

Contact Person: David A Wilson, PhD, 

Scientific Review Officer, Review Branch/ 

DERA, National Heart, Lung, and Blood 

Institute, 6701 Rockledge Drive, Room 7204, 

Bethesda, MD 20892–7924, 301–435–0299, 

wilsonda2@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: October 22, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–27319 Filed 10–28–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, Office 

of Infectious Diseases (BSC, OID) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Time and Date: 10:30 a.m.–12 p.m., 

November 15, 2010. 

Place: Teleconference. 

Status: Open to the public, the toll 

free dial in number is 1(800)369–1755 

with a pass code of 8481618. 

Purpose: The BSC, OID, shall advise 

the Secretary, Department of Health and 

Human Services; the Director, CDC; the 

Director, OID; and the Directors of the 

National Center for Immunization and 

Respiratory Diseases, the National 

Center for Emerging and Zoonotic 

Infectious Diseases, and the National 

Center for HIV/AIDS, Viral Hepatitis, 

STD, and TB Prevention, CDC, 

concerning strategies, goals, and 

priorities for the programs and research 

within the national centers and monitor 

the overall strategic direction and focus 

of OID and the national centers. 

Matters To Be Discussed: The meeting 

will involve the presentation of a draft 

document being developed to advance 

CDC’s infectious disease priorities. A 

subsequent meeting to solicit further 

discussion and input on the document 

from the board is currently scheduled 

for December 6, 2010 and will be 

announced at a future date. 

Requests for a copy of the draft 

document may be sent to 

ddidinput@cdc.gov prior to the 

teleconference. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Robin Moseley, CDC, OID, 1600 Clifton 

Road, NE., Mailstop D–10, Atlanta, 

Georgia 30333, telephone (404) 639– 

4461. 

The Director, Management and 

Analysis Services Office, has been 

delegated the authority to sign the 

Federal Register notices pertaining to 

announcements of meetings and other 

committee management activities for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: October 22, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–27462 Filed 10–28–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meetings 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of meetings of the Sleep 

Disorders Research Advisory Board. 

The meetings will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Sleep Disorders 

Research Advisory Board. 

Date: November 12, 2010. 

Time: 3 p.m. to 5 p.m. 

Agenda: To discuss sleep research 

programs and sleep research strategic 

planning. Public meeting observers should 

call 1–800–779–2608 to access the 

teleconference and the observer passcode is 

7989226. Public meeting observers should 

send comments or questions for this meeting 

to the National Center on Sleep Disorders 

Research by e-mail mt2d@nih.gov or fax 301– 

480–3557. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Suite 10170, Bethesda, MD 

20892 (Telephone Conference Call.) 

Contact Person: Michael J Twery, PhD, 

Director, National Center on Sleep Disorders 

Research, Division of Lung Diseases, National 

Heart, Lung, and Blood Institute, National 

Institutes of Health, 6701 Rockledge Drive, 

Suite 10038, Bethesda, MD 20892–7952, 301– 

435–0199, twerym@nhlbi.nih.gov. 

Name of Committee: Sleep Disorders 

Research Advisory Board. 

Date: December 10, 2010. 

Time: 8:30 a.m. to 4 p.m. 

Agenda: To discuss sleep research 

programs and sleep research strategic 

planning. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, C–Wing, 

Conference Room 6, Bethesda, MD 20892. 

Contact Person: Michael J Twery, PhD, 

Director, National Center on Sleep Disorders 

Research, Division of Lung Diseases, National 

Heart, Lung, and Blood Institute, National 

Institutes of Health, 6701 Rockledge Drive, 

Suite 10038, Bethesda, MD 20892–7952,301– 

435–0199, twerym@nhlbi.nih.gov. 

Any interested person may file written 

comments with the committee by 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

Federal Register / Vol. 75, No. 209 / Friday, October 29, 2010 / Notices 66773 

forwarding the statement to the Contact 

Person listed on this notice. The 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for 

entrance onto the NIH campus. All 

visitor vehicles, including taxicabs, 

hotel, and airport shuttles will be 

inspected before being allowed on 

campus. Visitors will be asked to show 

one form of identification (for example, 

a government-issued photo ID, driver’s 

license, or passport) and to state the 

purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nhlbi.nih.gov/meetings/index.htm, 

where an agenda and any additional 

information for the meeting will be 

posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: October 22, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–27318 Filed 10–28–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Pediatric Oncology Subcommittee of 

the Oncologic Drugs Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Pediatric 

Oncology Subcommittee of the 

Oncologic Drugs Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on November 30, 2010, from 8 a.m. 

to 5:30 p.m. 

Location: FDA White Oak Campus, 

10903 New Hampshire Ave., Bldg. 31, 

the Great Room, White Oak Conference 

Center (Rm. 1503), Silver Spring, MD 

20993–0002. 

Contact Person: Nicole Vesely, Center 

for Drug Evaluation and Research, Food 

and Drug Administration, 10903 New 

Hampshire Ave., Bldg. 31, Rm. 2417, 

Silver Spring, MD 20993–0002, 301– 

796–9001, FAX: 301–847–8533, e-mail: 

nicole.vesely@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512542. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On November 30, 2010, 

information will be presented regarding 

pediatric development plans for four 

products that were either recently 

approved by FDA or, are in late stage 

development for an adult oncology 

indication. The subcommittee will 

consider and discuss issues relating to 

the development of each product for 

pediatric use and provide guidance to 

facilitate the formulation of Written 

Requests for pediatric studies, if 

appropriate. The four products under 

consideration are: (1) Crizotinib, 

manufactured by Pfizer, Inc.; (2) 

pralatrexate, manufactured by Allos 

Therapeutics, Inc.; (3) denosumab, 

manufactured by Amgen, Inc.; and (4) 

eribulin, manufactured by Eisai Inc. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the subcommittee. Written 

submissions may be made to the contact 

person on or before November 15, 2010. 

Oral presentations from the public will 

be scheduled between approximately 

9:15 a.m. to 9:30 a.m., 11:15 a.m. to 

11:30 a.m., 2:05 p.m. to 2:20 p.m., and 

4:10 p.m. to 4:25 p.m. Those desiring to 

make formal oral presentations should 

notify the contact person and submit a 

brief statement of the general nature of 

the evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before November 4, 2010. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

November 5, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Nicole 

Vesely at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 25, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–27322 Filed 10–28–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–5383–N–24] 

Notice of Proposed Information 

Collection for Public Comment; FY 

2010 Capital Fund Community and 

Education Training Facilities NOFA 

AGENCY: Office of the Assistant 

Secretary for Public and Indian 

Housing, HUD. 

ACTION: Notice. 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES